Why Pharma's Data Security Model Is Built for a World That No Longer Exists

Your IND filing is under regulatory review. Your formulation team is collaborating with a CMO in Singapore. Your business development team is sharing a data room with three potential acquirers. And your AI platform is summarizing clinical trial data to accelerate your next submission.

All of this is standard operating procedure. All of it moves your most sensitive IP outside your environment. And in every one of those scenarios, the moment the data leaves, you lose control of it.

The Operating Model Changed. Security Didn't.

Pharma today runs on a distributed network of CROs, CMOs, regulatory partners, AI vendors, and M&A counterparties. Data moves constantly and intentionally; not because of a breach, but because that's how the industry works. Trial data travels to contract labs. Draft filings circulate among outside counsel and regulatory consultants. Diligence packages land in third-party VDRs.

The security stack most organizations have in place was designed for a different era - one where sensitive data lived inside the perimeter, and access controls kept it there. That assumption no longer holds. According to the IBM 2023 Cost of a Data Breach Report, the average healthcare breach now costs $10.9 million — the highest of any sector. And according to Help Net Security, 87% of healthcare and pharma companies have been negatively affected by breaches originating in their third-party ecosystems.

The problem is structural, not technical. The tools haven't failed. The model has.

Where the Exposure Actually Lives

Why are third-party partners the biggest data security risk in pharma?

Your security controls govern your environment. They don't govern your CRO's, your CMOs, or your regulatory consultants. Every file shared across that network is a file you no longer control, regardless of compliance certifications, NDAs, or vendor risk assessments. When a partner is breached, and statistically, they will be, your data is in the blast radius. The 2025 Verizon Data Breach Investigations Report found that third-party involvement in breaches doubled year over year, accounting for 30% of all confirmed incidents.

Why are draft regulatory filings more valuable to attackers than final submissions?

The industry protects final regulatory submissions carefully. It is far less careful with the documents that precede them. Draft IND, NDA, and BLA filings contain the reasoning, formulation logic, trial design decisions, and regulatory strategy that took years to develop. A competitor with access to that draft doesn't need to steal your molecule. The underlying intellectual work is the asset. And that work moves across CROs, CMOs, and partners constantly, in formats that standard DLP and access controls were never designed to protect.

How does AI create data security risks in pharmaceutical organizations?

Every AI system with access to your documents — Copilot, a RAG pipeline, an LLM-based regulatory assistant — is a potential exfiltration pathway. These systems treat all accessible data as usable. They have no concept of sensitivity, privilege, or the difference between a finalized filing and a draft containing competitive reasoning. The control failure doesn't require a breach; it requires a permissions misconfiguration, an overly permissive integration, or a prompt that retrieves more than it should.

What do FDA, HIPAA, and GDPR require for data access control in pharma?

FDA, HIPAA, and GDPR are moving toward cryptographic proof of access control — not documentation. Audit logs, data handling policies, and compliance certifications describe intent. They don't demonstrate that access was actually controlled at the data level. Regulators increasingly understand this distinction, and the gap between what organizations can document and what they can prove is becoming a meaningful compliance exposure.

What is data-centric security in pharma?

Data-centric security protects the data itself rather than the systems that store or transmit it. In pharma, this means applying encryption and access controls at the document or field level so that protection travels with the file — to CROs, CMOs, regulatory partners, or AI platforms — and persists regardless of where the data resides or who controls the infrastructure it passes through.

Why Standard Tools Don't Close the Gap

Most organizations believe they have solved this problem. They haven't. Three false assumptions underlie the gap, and each maps directly to a scenario that pharma companies face daily.

What is the difference between access control and data control?

Access control governs who can reach a file through permissions, identity management, and network controls. Data control governs what happens to the data after someone accesses it. Once a file is downloaded, forwarded, or ingested by an AI system, access controls no longer apply. Data control that involves persistent encryption tied to the file is the only mechanism that protects data after it leaves the environment.

The second assumption is that encryption solves the problem. Encryption at rest and in transit protects data while it's stored or moving between systems. It stops at the file boundary. When an authorized user opens that file, the data is unencrypted and fully accessible; to them, to any AI system they use, and to anyone who subsequently obtains the file.

The third is that AI governance can wait. AI pipelines are already running on documents across pharma organizations. The integrations are live. The question is not whether AI will access sensitive data — it's whether that access is governed, and in most organizations today, it isn't.

What Persistent Control Actually Looks Like

The model that closes this gap is straightforward: protection that travels with the file, not the system.

How does persistent data protection work in clinical trials and regulatory submissions?

Persistent data protection applies encryption and access controls at the document or field level before data leaves the organization. In clinical trials, PHI shared across CROs retains access controls and audit trails after download, satisfying both FDA and GDPR requirements. In regulatory submissions, draft filings are protected at the field level, allowing legal and regulatory teams to collaborate without exposing the full document to every reviewer. When a CRO is breached, a deal falls through, or a reviewer's authorization expires, access is revoked, even for files that have already been downloaded.

Three capabilities define this model in practice. First, encrypt before data moves — at the field, section, or document level, tied to sensitivity rather than storage location. Second, keep control of the file, including access rules, audit trails, and revocation logic that travel with the document rather than residing in a separate system. Third, prove it; every access event is logged and cryptographically tied to the document, producing embedded proof ready for FDA, HIPAA, or any regulatory inquiry.

This applies across the pharma operating model: clinical trial data packages shared with CROs, IND and NDA drafts circulating among regulatory counsel, M&A diligence rooms where access needs to end when the deal does, and AI pipelines where only authorized data should enter.

Can pharma companies revoke access to files already shared with CROs or partners?

Yes - if the protection is embedded in the file rather than the system. Traditional access controls can only revoke access to files still within a managed environment. Persistent, document-level encryption allows organizations to revoke access to a file anywhere it resides, including on a partner's device, in a downloaded copy, or inside a third-party AI workflow, by updating the access policy tied to the document itself.

The Proof Problem

Regulators are not asking for better policies. They are asking for evidence. The direction of travel across FDA, HIPAA, and GDPR is toward cryptographic proof of access control — a demonstrable record showing that data was accessible only to authorized parties, at specified times, under defined conditions.

This matters more in pharma than almost any other sector. Clinical trial data sharing involves PHI moving across international borders and through multiple vendor environments. Regulatory submissions are scrutinized for data integrity, not just content. M&A transactions create data access obligations that survive the deal itself. In each of these contexts, the question a regulator or auditor will eventually ask is not "did you have a policy" — it's "can you prove what happened."

Documentation describes what you intended to do. Cryptographic audit trails embedded in the document itself show what actually happened. For pharma organizations facing increasing scrutiny across data sharing agreements, AI adoption disclosures, and third-party risk, the ability to produce that proof on demand is becoming a competitive differentiator, not just a compliance requirement.

Confidencial.io: Control That Travels With the File

Confidencial applies selective encryption at the field, section, or document level, all before data leaves your environment. Access rules, revocation logic, and cryptographic audit trails are embedded in the document itself, not in a separate system that can be bypassed or siloed. When a partner is breached, a diligence process ends, or an AI integration exceeds its authorization, you revoke access to files that are already shared, already downloaded, or already in transit.

Security teams across North America and Europe are using this approach to govern clinical trial data sharing, protect draft regulatory filings, manage M&A diligence exposure, and control what enters AI pipelines. The result is not a new perimeter. It's the elimination of the assumption that a perimeter is sufficient.

You can't control your business associate's security. However, you can control what happens to your data when theirs fails.